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TO THE EDITOR
Atopic dermatitis (AD) is a common
chronic inflammatory skin disease char-
acterized by itchy, inflamed skin (Cook-
son et al., 2001). Onset of disease is
mainly in infancy and early childhood
with a prevalence up to 10–20% of
children living in Western Europe (Roll
et al., 2004). AD is a multifactorial
disease with environmental as well as
genetic factors influencing disease sus-
ceptibility.
Genome-wide linkage studies for
AD revealed significant linkage to a
region on chromosome 1q21, named
epidermal differentiation complex
(Cookson et al., 2001). This region
harbors genes that fulfil important
functions in terminal differentiation of
the human epidermis (Mischke et al.,
1996). Recently, it has been reported
that two loss-of-function mutations,
R501X and 2282del4, within the filag-
grin (FLG) gene located in the epider-
mal differentiation complex are associ-
ated with AD (Palmer et al., 2006;
Weidinger et al., 2006). These muta-
tions, originally identified in families
with ichthyosis vulgaris, showed highly
significant associations with AD and/or
asthma in Irish, Scottish, and Danish
cohorts (Palmer et al., 2006). Subse-
quently, a family-based association
analysis of German AD patients re-
vealed significant association of the two
loss-of-function mutations with AD,
especially with the extrinsic subtype
characterized by elevated IgE levels
and concomitant allergic sensitizations
(Weidinger et al., 2006).
For replication of these associations,
we screened 378 unrelated AD patients
of German origin for the presence of
these two mutations, including 210
patients with age of onset before 2
years. All patients were recruited by a
consultant specialist for AD (Q.P.,
Gladbeck, Germany) and the AD diag-
nosis was based on the criteria devel-
oped by Hanifin and Rajka (1980). Two
hundred and sixty-five control samples
from adults of at least 40 years of age
without AD or allergic diseases were
recruited by the same physician. Ad-
ditionally, 433 healthy blood donors
were recruited at the University Hospi-
tal of Essen, Germany. The study was
performed according to the the De-
claration of Helsinki Principles and
approved by the local Ethics Committee
of the Ruhr-University of Bochum,
Germany. Informed consent was ob-
tained for all subjects. Clinical informa-
tion about the case and control cohorts
is summarized in Table 1. The R501X
and 2282del4 mutations were geno-
typed by restriction enzyme digestion
as described previously (Palmer et al.,
2006). Allele and genotype frequencies
were compared between groups using
the w2 test. P-values were not adjusted
for multiple testing as the performed
analyses did not constitute independent
tests.
In our cohort, the combined allele
frequency of the two mutations was
5.1% in healthy controls, 8.7% in all
AD patients, 10.3% in patients with age
of onset in childhood, and 12.1% in AD
patients with age of onset before 2
years, yielding significant associations
of the combined allele frequencies of all
three subgroups compared to healthy
controls (P¼ 0.001, P¼ 3.6 105, and
P¼7.6107, respectively; Table 2).
The allele frequencies reported here
are comparable to the ones described
in a Danish birth cohort (9.5% in AD
patients vs 4.2% in individuals without
AD), whereas the combined allele
frequency in the Irish pediatric AD
cohort was much higher (33.0%)
(Palmer et al., 2006). This latter cohort
comprised only 52 patients and
thus, the reported allele frequency still
has to be refined for the general
population.
It is noteworthy that we found the
strongest association of FLG null-muta-
tions with AD within the subgroup of
patients with early onset of the disease
(p2 years of age). In this group, 21.3%
of patients carried one or more FLG
null-alleles, compared to only 9.6%
in controls (P¼ 8.45106). In our
cohort, four out of six patients were
homozygous for the 2282del4 allele,
one patient was typed as compound
heterozygous for the two mutations and
one patient had the R501X mutation in
homozygous state. All of these six
patients had an onset of AD before
2 years of age. Thus, our results indicate
that these mutations are also associated
with age of onset of AD. This latter
observation is in contrast to the findings
of Weidinger et al. (2006) who did not
see an obvious correlation between the
presence of FLG-null mutations and
early onset of AD.
An intact epidermal barrier is of
great importance for preventing sensiti-
zation to allergens. The FLG protein is
an essential element of the human
epidermis and crucial for maintaining
this barrier function (Hudson, 2006).
Immunohistochemical analysis of skin
biopsies of patients with ichthyosis
vulgaris revealed that each of the two
investigated mutations results in com-
plete loss of FLG peptide produc-
tion (Smith et al., 2006). Thus, heritable
skin barrier defects seem to play an
important role in AD pathogenesis in
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addition to dysregulation phenomena
in adaptive and innate immunity.
Further, disruption of the epidermal
barrier function caused by FLG muta-
tions may potentially facilitate allergic
sensitization in AD patients.
Ichthyosis vulgaris and AD share
some clinical features, including dry
scaly skin, keratosis pilaris, and palmar
hyperlinearity (Weidinger et al., 2006).
The FLG loss-of-function mutations
were first described as the cause of
Table 1. Clinical data of the AD and control cohorts
AD Healthy controls
Number of subjects 378 700
Gender: F/M 224/153 361/339
Ethnicity German German
Age at enrollment 7.25 years (range 0.5–72) 50.2 years (range 19–87)
Age of onset o2 years: 210 (55.5%) —
o18 years: 281 (74.3%) —
Elevated IgE levels (470 kU/l) 134/216 (62%) —
AD, atopic dermatitis; F, female, IgE, immunoglobulin E; M, male.
Table 2. Genotype and allele frequencies of the investigated FLG mutations in all AD patients, patients with onset
of AD in childhood and onset of AD before age of 2 years in comparison to healthy controls
Mutation Genotype Allele All AD patients AD onset in childhood AD onset p2 years Healthy controls
R501X R/R 364 (96.3%) 269 (95.7%) 199 (94.8%) 680 (97.1%)
R/X 13 (3.4%) 11 (3.9%) 10 (4.8%) 18 (2.6%)
X/X 1 (0.3%) 1 (0.4%) 1 (0.5%) 2 (0.3%)
n 378 281 210 700
P versus controls 0.42 0.26 0.11
R 741 (98.0%) 549 (97.7%) 408 (97.1%) 1,378 (98.4%)
X 15 (2.0%) 13 (2.3%) 12 (2.9%) 22 (1.6%)
n 756 562 420 1,400
P versus controls 0.48 0.26 0.09
2282del4 AA 328 (87.7%) 237 (85.6%) 173 (83.6%) 632 (93.2%)
Aa 42 (11.2%) 36 (13.0%) 30 (14.5%) 45 (6.6%)
aa 4 (1.1%) 4 (1.4%) 4 (1.9%) 1 (0.1%)
n 374 277 207 678
P versus controls 0.008* 0.001* 2.8 104*
A 698 (93.3%) 510 (92.1%) 376 (90.8%) 1,309 (96.5%)
a 50 (6.7%) 44 (7.9%) 38 (9.2%) 47 (3.5%)
n 748 554 414 1,356
P versus controls 7.5 104* 3.1105* 1.95 106*
Combined AA 315 (84.2%) 226 (84.2%) 163 (78.7%) 603 (90.4%)
Aa 53 (14.2%) 45 (14.2%) 38 (18.4%) 26 (9.0%)
aa 6 (1.6%) 6 (1.6%) 6 (2.9%) 1 (0.6%)
n 374 277 207 667
P versus controls 0.008* 9.2104* 1.2 104*
A 683 (91.3%) 497 (89.7%) 364 (87.9%) 1,266 (94.9%)
a 65 (8.7%) 57 (10.3%) 50 (12.1%) 68 (5.1%)
n 748 554 414 1,334
P versus controls 0.001* 3.6105* 7.6 107*
AD, atopic dermatitis; FLG, filaggrin.
*Significantly different (Po0.05).
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moderate or severe ichthyosis vulgaris
in 15 families and isolated cases (Smith
et al., 2006). In a recent case report
of six Irish families with ichthyosis
vulgaris and AD, a third FLG mutation,
3702delG, was found in one family in
heterozygous state (Sandilands et al.,
2006). This mutation was not found in
B380 healthy controls. As this muta-
tion appears so rare, we did not
evaluate it in our AD cohort.
In conclusion, we found a significant
association of two FLG loss-of-function
mutations with AD, especially with
early onset of the disease. Thus, we
were able to replicate and extend the
findings of earlier studies, suggesting
that these variations may play an
important role in AD pathogenesis.
Replication studies are highly important
for complex genetic diseases to rule out
that an observed association is not
owing to chance. Further studies in
additional populations will reveal the
precise relationship between FLG var-
iations and atopic disease.
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TO THE EDITOR
Atopic dermatitis (AD) arises from the
interaction between strong genetic and
environmental factors (Morar et al.,
2006). As it commonly occurs in con-
cert with asthma and/or hay fever, and
the majority of patients exhibits ele-
vated serum IgE levels and/or sensitiz-
ations against aero- and food allergens,
most pathophysiological concepts are
dominated by atopic mechanisms and
regard IgE-mediated sensitization as
central cornerstone in the development
of AD (Akdis et al., 2006). However,
there is accumulating evidence from
epidemiological studies, suggesting that
sensitization is not essential for the
development of eczema and that atopy
may be secondary rather than causative
(Williams and Flohr, 2006). In addition,
genome-wide screens and candidate
gene studies have shown only partial
overlap of AD with other atopic pheno-
types, but a closer relationship with
other epithelial diseases such as psoria-
sis (Cookson, 2004). Thus, attention has
been drawn to the impaired epidermal
barrier function, which is a hallmark
feature of AD. In this context, the
epidermal differentiation complex on
chromosome 1q21, for which linkage
to both AD and psoriasis has been
reported, is of particular interest, as it
harbors a number of genes and gene
families expressed in the terminally
differentiating epithelium (Cookson
et al., 2001). Recently, it was demon-
strated that two functional mutations
within the epidermal differentiation
complex gene filaggrin (FLG), underlie
ichthyosis vulgaris (Smith et al., 2006)
and are strong risk factors for AD and
asthma in the context of AD in European
populations (Palmer et al., 2006). In aAbbreviations: AD, atopic dermatitis; FLG, filaggrin
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